PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16386505-6	2005	PARP-1 showed a statistically significant relationship with the time required to achieve effective diuresis (Rho:0.779), with serum creatinine, and with duration of cold ischemia (Rho:0.803).	Creatinine	132-142	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6	
16386505-8	2005	In conclusion, multivariate analysis demonstrated that PARP-1 expression and cold ischemia duration in kidney biopsies with ATN predicted the short-term delay in total recovery of renal function and serum creatinine in the first month.	Creatinine	205-215	poly(ADP-ribose) polymerase 1	Homo sapiens	55-61	
19784367-5	2009	RESULTS: PARP-1 expression showed a significant relationship with cold ischemia time (r coefficient = 0.603), time to effective diuresis (r = 0.770), serum creatinine levels at biopsy (r = 0.649), and degree of ATN (r = 0.810) (p = 0.001, Pearson test).	Creatinine	156-166	poly(ADP-ribose) polymerase 1	Homo sapiens	9-15	
15866623-5	2005	The increase in the immunohistochemical expression of PARP-1 showed a statistically significant relationship with the duration of cold ischemia, with serum creatinine levels, and with the time required to achieve effective diuresis (P < .0001, Spearman test).	Creatinine	156-166	poly(ADP-ribose) polymerase 1	Homo sapiens	54-60	
15866623-6	2005	Cold ischemia of >24 hours and serum creatinine levels >1.7 mg/dL showed a statistically significant relationship with the highest PARP-1 expression levels (2.83 +/- 0.4 vs 1.36 +/- 0.8, P < .0001, Mann-Whitney U test).	Creatinine	40-50	poly(ADP-ribose) polymerase 1	Homo sapiens	137-143	
15110646-6	2004	RESULTS: Immunohistochemical expression of PARP-1 showed a statistically significant relationship with donor age (r =.408, P =.006, Spearman test), with time required to achieve effective diuresis (r =.386, P =.01, Spearman test) and with creatinine levels in the first 3 months.	Creatinine	239-249	poly(ADP-ribose) polymerase 1	Homo sapiens	43-49	
31792084-1	2020	OBJECTIVE: To describe discrepancies in calculated and measured glomerular filtration rate in patients using PARP (poly ADP ribose polymerase) inhibitors who had an elevation in serum creatinine levels.	Creatinine	184-194	poly(ADP-ribose) polymerase 1	Homo sapiens	109-113	
31792084-1	2020	OBJECTIVE: To describe discrepancies in calculated and measured glomerular filtration rate in patients using PARP (poly ADP ribose polymerase) inhibitors who had an elevation in serum creatinine levels.	Creatinine	184-194	poly(ADP-ribose) polymerase 1	Homo sapiens	115-141	
31792084-12	2020	CONCLUSIONS: Serum creatinine elevation in patients taking PARP inhibitors may not be associated with a true decrease in glomerular filtration rate.	Creatinine	19-29	poly(ADP-ribose) polymerase 1	Homo sapiens	59-63	
31792084-13	2020	A high index of suspicion should be maintained for alternative causes of elevated serum creatinine in patients treated with PARP inhibitors who lack other sources of renal injury.	Creatinine	88-98	poly(ADP-ribose) polymerase 1	Homo sapiens	124-128	
17889105-11	2007	A significant relationship with PARP-1 expression was demonstrated with renal function (effective diuresis, serum creatinine levels) and pretransplant cold ischemia time (P < .001).	Creatinine	114-124	poly(ADP-ribose) polymerase 1	Homo sapiens	32-38